Latest / Cork News Today | 2 Min News | The Daily News Now!
Skyclarys Decision: Ireland’s Rare Disease Crossroads | Cork News
A groundbreaking drug called Skyclarys could be the first to slow neurological damage in Friedreich’s ataxia, a rare genetic disorder affecting around 200 people in Ireland. While Biogen disputes the HSE’s €280,000 annual cost per patient, families, the Taoiseach, and Rare Disease Ireland are urging the government to act — with the HSE set to make a final decision today on whether to fund this potentially life-changing treatment. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:advertise@thednn.ai This is an automated, high-level news…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.